Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of majo…
Biotechnology
US, New York [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Axsome Therapeutics, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2022 | -3.5900 | -4.333 | 0 | 46 | -134 | -196 | -124 | 12 | -125 | 12 | 66 | 69 |
| 2023 | -4.8600 | -4.264 | 50 | 268 | -197 | -197 | -170 | 72 | -176 | 71 | 159 | 395 |
| 2024 | -5.2700 | -5.629 | 270 | 373 | -239 | -255 | -176 | 100 | -182 | 98 | 323 | 551 |
| 2025 | - | -1.671 | - | 632 | - | -109 | - | 170 | - | 167 | - | 933 |
| 2026 | - | 2.F4X/td> | - | 2.F4X/td> | - | 2.F4X/td> | - | 2.F41/td> | - | 2.F41 | - | 2.F41 |
| 2027 | - | 1.F5X/td> | - | 1.F5X/td> | - | 1.F5X/td> | - | 1.F51/td> | - | 1.F51 | - | 1.F51 |
| 2028 | - | 0.F6X/td> | - | 0.F6X/td> | - | 0.F6X/td> | - | 0.F61/td> | - | 0.F61 | - | 0.F61 |